ZHEN WANG¹, JUN FU¹, SAISAI ZHU¹, HAODONG TANG², KUI SHI¹, JIHUA YANG³, MENG WANG³, MENGGE WU¹, DUNFENG QI^1,*

Oncology Research, Vol.32, No.12, pp. 1851-1866, 2024, DOI:10.32604/or.2024.055286 - 13 November 2024

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) has a rich and complex tumor immune microenvironment (TIME). M2 macrophages are among the most extensively infiltrated immune cells in the TIME and are necessary for the growth and migration of cancers. However, the mechanisms and targets mediating M2 macrophage infiltration in pancreatic cancer remain elusive. Methods: The M2 macrophage infiltration score of patients was assessed using the xCell algorithm. Using weighted gene co-expression network analysis (WGCNA), module genes associated with M2 macrophages were identified, and a predictive model was designed. The variations in immunological cell patterns, cancer mutations, and… More > Graphic Abstract

Luda Chen¹, Kuangzhu Bao², Ying Chen², Jingang Hao^2,*, Jianfeng He^1,3,*

CMC-Computers, Materials & Continua, Vol.79, No.1, pp. 409-427, 2024, DOI:10.32604/cmc.2024.048507 - 25 April 2024

Abstract Pancreatic diseases, including mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC), present with similar imaging features, leading to diagnostic complexities. Deep Learning (DL) methods have been shown to perform well on diagnostic tasks. Existing DL pancreatic lesion diagnosis studies based on Magnetic Resonance Imaging (MRI) utilize the prior information to guide models to focus on the lesion region. However, over-reliance on prior information may ignore the background information that is helpful for diagnosis. This study verifies the diagnostic significance of the background information using a clinical dataset. Consequently, the Prior Difference Guidance Network (PDGNet)… More >

SANDRA STICKLER, BARBARA RATH, GERHARD HAMILTON^*

Oncology Research, Vol.32, No.5, pp. 799-805, 2024, DOI:10.32604/or.2024.045356 - 23 April 2024

Abstract Pancreatic cancer has a dismal prognosis due to late detection and lack of efficient therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all pancreatic ductal adenocarcinomas (PDACs) and constitutes an attractive target for therapy. However, the most common KRAS mutations in PDAC are G12D (44%), G12V (34%) and G12R (20%) that are not amenable to treatment by KRAS G12C-directed cysteine-reactive KRAS inhibitors such as Sotorasib and Adagrasib that exhibit clinical efficacy in lung cancer. KRAS G12C mutant pancreatic cancer has been treated with Sotorasib but this mutation is More >

HYUNG SUN KIM^1,#, YUN SUN LEE^2,#, SEUNG MYUNG DONG³, HYO JUNG KIM¹, DA EUN LEE², HYEON WOONG KANG², MYEONG JIN KIM², JOON SEONG PARK^1,*

Oncology Research, Vol.32, No.4, pp. 615-624, 2024, DOI:10.32604/or.2024.044029 - 20 March 2024

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies. A specific mechanism of its metastasis has not been established. In this study, we investigated whether Neural Wiskott-Aldrich syndrome protein (N-WASP) plays a role in distant metastasis of PDAC. We found that N-WASP is markedly expressed in clinical patients with PDAC. Clinical analysis showed a notably more distant metastatic pattern in the N-WASP-high group compared to the N-WASP-low group. N-WASP was noted to be a novel mediator of epithelial-mesenchymal transition (EMT) via gene expression profile studies. Knockdown of N-WASP in pancreatic cancer cells… More > Graphic Abstract

DONGQIN WANG^1,4, YAN SHI¹, ZHIQIANG WANG⁴, JING ZHANG², LUYAO WANG², HONGYU MA³, SHUHUA SHI², XIAOFU LIAN², HUA HUANG⁴, XIAOJING WANG^1,*, CHAOQUN LIAN^4,*

BIOCELL, Vol.48, No.1, pp. 111-122, 2024, DOI:10.32604/biocell.2023.046903 - 30 January 2024

Abstract Introduction: Among all malignant tumors of the digestive system, pancreatic carcinoma exhibits the highest mortality rate. Currently, prevention and effective treatment are urgent issues that need to be addressed. Methods: The study focused on meiotic nuclear divisions 1 (MND1), integrating data from the Gene Expression Profiling Interactive Analysis (GEPIA) database with prognostic survival analysis. Simultaneously, experiments at cellular level were employed to demonstrate the effect of MND1 on the proliferation and migration of PC. The small-molecule inhibitor of MND1 was used to suppress the migration of PC cells by knocking down MND1 using small interfering… More >

Amit Saxena¹, Smita Saxena^2,*

Journal of Quantum Computing, Vol.5, pp. 1-13, 2023, DOI:10.32604/jqc.2023.044555 - 09 November 2023

Abstract Quantum computing is a promising new approach to tackle the complex real-world computational problems by harnessing the power of quantum mechanics principles. The inherent parallelism and exponential computational power of quantum systems hold the potential to outpace classical counterparts in solving complex optimization problems, which are pervasive in machine learning. Quantum Support Vector Machine (QSVM) is a quantum machine learning algorithm inspired by classical Support Vector Machine (SVM) that exploits quantum parallelism to efficiently classify data points in high-dimensional feature spaces. We provide a comprehensive overview of the underlying principles of QSVM, elucidating how different… More >

XUEFENG WANG^1,#, SICONG JIANG^2,#, XINHONG ZHOU³, XIAOFENG WANG⁴, LAN LI⁵, JIANJUN TANG^1,*

Oncology Research, Vol.31, No.5, pp. 697-714, 2023, DOI:10.32604/or.2023.029458 - 21 July 2023

Abstract Background: Pancreatic cancer is associated with high mortality and is one of the most aggressive of malignancies, but studies have not fully evaluated its molecular subtypes, prognosis and response to immunotherapy of different subtypes. The purpose of this study was to explore the molecular subtypes and the key genes associated with the prognosis of pancreas cancer patients and study the clinical phenotype, prognosis and response to immunotherapy using single-cell seq data and bulk RNA seq data, and data retrieved from GEO and TCGA databases. Methods: Single-cell seq data and bioinformatics methods were used in this… More >

CHIWEN BU^1,2, LIGANG ZHAO¹, LISHAN WANG¹, ZEQIAN YU¹, JIAHUA ZHOU^1,*

Oncology Research, Vol.31, No.4, pp. 495-503, 2023, DOI:10.32604/or.2023.029309 - 25 June 2023

Abstract Pancreatic cancer is one of the most aggressive cancers with a median survival time of less than 5 months, and conventional chemotherapeutics are the main treatment strategy. Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new era for targeted therapy for this disease. However, most pancreatic cancer patients carry wild-type BRCA1/2 with resistance to PARP inhibitors. Here, we reported that mammalian target of rapamycin complex 2 (mTORC2) kinase is overexpressed in pancreatic cancer tissues and promotes pancreatic cancer cell growth and invasion. Moreover, we found that knockdown of the More > Graphic Abstract

XIN LI^1,2,#, WENKAI JIANG^3,#, WANCHENG LI^3,#, SHI DONG³, YAN DU³, HUI ZHANG^1,*, WENCE ZHOU^1,3,*

Oncology Research, Vol.31, No.4, pp. 505-514, 2023, DOI:10.32604/or.2023.026959 - 25 June 2023

Abstract Background: The dilemma of pancreatic cancer treatment has become a global challenge. For this reason, effective, feasible, and new medical methods are currently much-needed. Betulinic acid (BA) has been valued as a potential therapy for pancreatic cancer. However, the mechanism by which BA exerts an inhibitory effect on the development of pancreatic cancer remains elusive. Methods: A rat model and two cell models of pancreatic cancer were established, and the effect of BA on pancreatic cancer was verified in vivo and in vitro by using MTT, Transwell, flow cytometry, RT-PCR, Elisa and immunohistochemistry. At the same time,… More > Graphic Abstract

HONG YANG^1,2, WAN LI^1,2, LIWEN REN^1,2, YIHUI YANG^1,2, YIZHI ZHANG^1,2, BINBIN GE^1,2, SHA LI^1,2, XIANGJIN ZHENG^1,2, JINYI LIU^1,2, SEN ZHANG^1,2, GUANHUA DU^1,2, BO TANG³, HONGQUAN WANG³, JINHUA WANG^1,2,*

Oncology Research, Vol.31, No.2, pp. 83-99, 2023, DOI:10.32604/or.2023.028905 - 10 April 2023

Abstract Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate, whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed. Early diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment regimens. So far, CA19-9 is the only biomarker for pancreatic cancer approved by the FDA, but its effectiveness is limited by low sensitivity and specificity. With recent advances in genomics, proteomics, metabolomics, and other analytical and sequencing technologies, the rapid acquisition and screening of biomarkers is now possible. Liquid biopsy also occupies More > Graphic Abstract